IFNA2 and melanoma: In phase II, flu-like symptoms such as headache, fatigue, IRRs, and nausea were among the most common TEAEs reported, most of which were grades 1–2, consistent with findings from the phase Ib KEYNOTE-029 study of pembrolizumab in combination with pegylated IFNα-2b in patients with advanced melanoma or renal cell carcinoma (23).